Form 4 for TVTX Travere Therapeutics, Inc.
Accepted 2026-04-15 21:48:44 ET · period of report 2026-04-13 · accession 0001698262-26-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-04-15 21:48 | 2026-04-13 | TVTX | ROTE WILLIAM E. | Chief Research Off | A - Grant | $0.00 | +14.0K | 123.1K | +13% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-04-13 | A | A | 14,000 | $0.00 | 123,087 | D | — | — | (F1) On January 31, 2025, the reporting person was granted performance restricted stock units (PSUs) which PSUs vested on April 13, 2026 upon the Issuer's confirmation that the U.S. Food and Drug Administration (FDA) had granted approval of FILSPARI (sparsentan) in FSGS. |